CD8A and hepatocellular carcinoma: In a preclinical study with the MycTg;KrasG12D hepatocellular carcinoma model, treatment of tumor-bearing mice with eFT-508 led to a significant increase in the number of cytotoxic CD8+ T-cells [13].